E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adverse events central nervus system after cycloplegics. EEG changes after cyclopentolate 1% |
Veranderingen centraal zenuw stelsel na cycloplegica. EEG veranderingen na cyclopentolaat 1%. |
|
E.1.1.1 | Medical condition in easily understood language |
Adverse events central nervus system after cycloplegics. EEG changes after cyclopentolate 1% |
Veranderingen centraal zenuw stelsel na cycloplegica. EEG veranderingen na cyclopentolaat 1%. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013760 |
E.1.2 | Term | Drug-induced extrapyramidal side effects |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare EEG pattern after cyclopentolate 1% with EEG pattern after placebo eye-drops.
Primary outcome
Detect if changes in EEG pattern are present after administration of two drops of cyclopentolate1% compared with placebo.
Secondary outcomes
Detect which pattern changes.
Detection of time of onset of EEG pattern change(s).
Detection of the amount and depth of EEG pattern change.
Detect factors (e.g. age, BMI etc.) that influences onset of- and/or changes in EEG pattern. |
Het vergelijken het EEG patroon na cyclopentolaat 1% met het EEG patroon na placebo oogdruppels.
Primaire uitkomst maat:
Detecteren van EEG veranderingen na toediening van twee druppels cyclopentolaat 1% vergeleken met (twee druppels) placebo.
Secundaire uitkomst maten:
Detecteren welk patroon veranderd.
Detecteren van tijd van onstaat van EEG veranderingen.
Detecteren van de hoeveelheid en ernst/diepte van de veranderingen.
Detecteren van faktoren (zoals leeftijd, BMI etc) die het onstaan en de soort en mate van veranderingen beinvloeden. |
|
E.2.2 | Secondary objectives of the trial |
To compare EEG pattern after cyclopentolate 1% with EEG pattern after placebo eye-drops.
Primary outcome
Detect if changes in EEG pattern are present after administration of two drops of cyclopentolate1% compared with placebo.
Secondary outcomes
Detect which pattern changes.
Detection of time of onset of EEG pattern change(s).
Detection of the amount and depth of EEG pattern change.
Detect factors (e.g. age, BMI etc.) that influences onset of- and/or changes in EEG pattern. |
Het vergelijken het EEG patroon na cycloplegica met het EEG patroon na placebo oogdruppels.
Primaire uitkomst maat:
Detecteren van EEG veranderingen na toediening van twee druppels cyclopentolaat 1% met (twee druppels) placebo.
Secundaire uitkomst maten:
Detecteren welk patroon veranderd.
Detecteren van tijd van onstaat van EEG veranderingen.
Detecteren van de hoeveelheid en ernst/diepte van de veranderingen.
Detecteren van faktoren (zoals leeftijd, BMI etc) die het onstaan en de soort en mate van veranderingen beinvloeden. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Healthy 6 to 16 year old volunteers, requiring an objective refraction because of standard departmental protocol, not having syndromes or diseases or behaviour or attention syndromes (e.g. ADHD or ADD or autism spectral conditions etc.) and possessing a normal or low BMI.
|
Gezonde 6 tot 16 jarige kinderen, gepland voor een objectieve refractie volgens standaard afdelings protocol, niet lijdend aan syndromen of ziektes of gedrags- of aandachts stoornissen (zoals ADHD, ADD, autistische spectrum stoornissen etc) en een normaal of laag BMI bezittend. |
|
E.4 | Principal exclusion criteria |
Not meeting the inclusion criteria:
Physical illness
Having syndomes or diseases or disorders in behaviour or attention (e.g. ADHD, ADD or autism like conditions etc)
Aged< 6 and >17 year
High BMI (overweight, obesitas) |
Niet voldoen aan de inclusie criteria
Lichamelijke ziekte
Lijden aan syndromen, ziektes of of gedrags- of aandachts stoornissen (zoals ADHD, ADD, autistische spectrum stoornissen etc)
Hoge BMI (overgewicht, obesitas)
Jonger dan 6 jaar of ouder dan 16 jaar zijn |
|
E.5 End points |
E.5.1 | Primary end point(s) |
This investigator initiated study is designed as a prospective, single-centre, cross sectional, quantitative, randomized single blind placebo-controlled trial.
The study investigate the presence, nature and severity of central nervus system changes with EEG recording and investigate risk factors for onset of central nervus system changes after two drops of cyclopentolate 1%. The duration will be approximately 12 months.
Randomized
• Two drops of cyclopentolate hydrochloride 1%, with an interval of 5 minutes in both eyes
or
• Placebo:
Primary outcome is to detect the presence of EEG pattern changes after administration of 2 drops of cyclopentolate 1%.
|
Dit onderzoek betreft een prospectieve, single-centre, cross sectioneel, kwantitatieve, enkel-blinde, placebo gecontroleerde, gerandomiseerde trial met herhaalde metingen.
De studie onderzoekt de aanwezigheid en de aard van centraal zenuwstelstel bijwerkingen met behulp van EEG onderzoek en tevens risico factoren voor het onstaan van deze bijwerkingen bij kinderen na 2 druppels cyclopentolaat 1%. De studie duur van zal ongeveer 1 jaar zijn; tot 24 proefpersonen de EEG onderzoeken compleet hebben afgerond.
Interventie:
Gerandomiseerd: Twee druppels cyclopentolaat hydrochloride 1%; interval 5 minuten of twee druppels placebo; interval 5 minuten.
Primaire uitkomst maat is het detecteren van EEG veranderingen na toediening van 2 druppels cyclopentolaat 1%
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The duration of the study will be approximately 12 months; untill 24 subjects completed the whole EEG measurements.
|
De studie duur zal ongeveer 1 jaar zijn; tot 24 proefpersonen de EEG onderzoeken compleet hebben afgerond.
|
|
E.5.2 | Secondary end point(s) |
Secondary outcomes are the kind of EEG pattern changes, detection of time of onset of EEG pattern changes, detection of the amount and depth of EEG pattern changes and detect factors that influences onset of- and/or changes in EEG pattern.
|
Secondary outcomes are the kind of EEG pattern changes, detection of time of onset of EEG pattern changes, detection of the amount and depth of EEG pattern changes and detect factors that influences onset of- and/or changes in EEG pattern. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The duration will be approximately 12 months untill 24 subjects completed the whole EEG measurements.
|
De studie duur zal ongeveer 1 jaar zijn; tot 24 proefpersonen de EEG onderzoeken compleet hebben afgerond.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The endpoint of study is defined as the moment all the measurements and reviews of have been done, all these data are admitted in SPSS database and the database is closed. |
The endpoint of study is defined as the moment all the measurements and reviews of have been done, all these data are admitted in SPSS database and the database is closed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |